VCM
ALT icon

Vines Capital Management’s Altimmune ALT Stock Holding History

Vines Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.4K Hold
18,884
– – 0.05% 90
2026
Q1 		$58.2K Buy
18,884
+1,000
+6% +$4.25K 0.06% 76
2025
Q4 		$64.6K Buy
+17,884
New +$78K 0.06% 73

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vines Capital Management's ALT Position: Q2 2026 in Review

Vines Capital Management held its Altimmune (ALT) position steady in Q2 2026 at 18,884 shares worth $57.4K. The position accounts for 0.05% of the portfolio, ranked #90.

Vines Capital Management first reported a position in ALT in Q4 2025 and has held it in 3 quarters since. The position peaked at $64.6K in Q4 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Vines Capital Management held 18,884 shares of Altimmune worth $57.4K as of Q2 2026.
  • Vines Capital Management left its Altimmune share count unchanged in Q2 2026.
  • Altimmune made up 0.05% of Vines Capital Management's portfolio in Q2 2026, its #90 holding.
  • Vines Capital Management first reported a position in Altimmune in Q4 2025 and has held it in 3 quarters since.
  • Vines Capital Management's Altimmune position peaked at $64.6K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Vines Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.